Literature DB >> 21735310

Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose.

Michael Levine1, Carrie A Truitt, Ayrn D O'Connor.   

Abstract

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor, recently approved for use in the USA for treatment of fibromyalgia. This case report describes a 59-year-old woman who ingested 3,000 mg of milnacipran in a suicide attempt. Following the ingestion, she became obtunded and developed autonomic instability. She required mechanical ventilation, treatment for hypertension, and then ultimately vasopressor support for refractory hypotension. In addition, she developed a transient, acute cardiac dysfunction with global hypokinesis and an ejection fraction of 30%. Resolution of the cardiac dysfunction was documented on repeat echocardiogram 2 days after the initial study. This was confirmed by cardiac catheterization performed 4 days after the acute ingestion in which coronary arteriogram was normal and left ventricular ejection fraction was 70%. Acute overdose was confirmed by quantification of plasma milnacipran concentration of 8,400 ng/mL obtained 5 h post-ingestion. To our knowledge, this represents the first case of cardiac toxicity complicating a milnacipran overdose in the medical literature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735310      PMCID: PMC3550178          DOI: 10.1007/s13181-011-0167-1

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  14 in total

1.  Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine.

Authors:  Marian Christoph; Bernd Ebner; Dirk Stolte; Karim Ibrahim; Steffen Kolschmann; Ruth H Strasser; Steffen Schön
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-07       Impact factor: 4.600

2.  Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.

Authors:  Masako Ikawa; Kazuo Yamada
Journal:  Clin Neuropharmacol       Date:  2010-05       Impact factor: 1.592

3.  Fatal intoxication with milnacipran.

Authors:  Laurent Fanton; Fabien Bévalot; Habdelhamid Grait; Catherine Le Meur; Yvan Gaillard; Daniel Malicier
Journal:  J Forensic Leg Med       Date:  2008-03-11       Impact factor: 1.614

4.  Serotonin syndrome after administration of milnacipran for fibromyalgia.

Authors:  Hussam A Yacoub; William G Johnson; Nizar Souayah
Journal:  Neurology       Date:  2010-02-23       Impact factor: 9.910

Review 5.  Efficacy and tolerability of milnacipran: an overview.

Authors:  S A Montgomery; J F Prost; A Solles; M Briley
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

Review 6.  Pharmacokinetics of milnacipran in comparison with other antidepressants.

Authors:  C Puozzo; B E Leonard
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

Review 7.  Preclinical pharmacology of milnacipran.

Authors:  M Briley; J F Prost; C Moret
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

8.  In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine.

Authors:  Yoshitaka Mitsumori; Yuji Nakamura; Kiyotaka Hoshiai; Yukitoshi Nagayama; Satomi Adachi-Akahane; Schuichi Koizumi; Masahiko Matsumoto; Atsushi Sugiyama
Journal:  Cardiovasc Toxicol       Date:  2010-12       Impact factor: 3.231

9.  A case of severe parkinsonism associated with short-term treatment with milnacipran.

Authors:  Toshifumi Muraoka; Eisaku Oku; Kazuhiro Sugataka; Shigeto Yamada
Journal:  Clin Neuropharmacol       Date:  2008 Sep-Oct       Impact factor: 1.592

10.  Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat.

Authors:  M B Assie; M Charveron; C Palmier; C Puozzo; C Moret; M Briley
Journal:  Neuropharmacology       Date:  1992-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.